Evolving novel anti-HER2 strategies

被引:107
作者
Jones, Kellie L. [1 ]
Buzdar, Aman U. [2 ]
机构
[1] Purdue Univ, Sch Pharm & Pharmaceut Sci, Indianapolis, IN USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
HER2-POSITIVE BREAST-CANCER; HER2/NEU E75 VACCINE; GROUP-STUDY I-01; PHASE-I; TRASTUZUMAB RESISTANCE; CLINICAL-TRIAL; TYROSINE KINASES; LAPATINIB; GROWTH; INHIBITOR;
D O I
10.1016/S1470-2045(09)70315-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The approval of trastuzumab for use in metastatic breast cancer marked a breakthrough in the understanding of the biology of the disease. However, like most cancer therapies, the disease finds a way to advance despite the treatments developed to eradicate it Although trastuzumab has had a large effect on the treatment of early and advanced-stage disease, a substantial proportion of patients with HER2-positive breast cancer still progress after receiving the drug. Potential mechanisms of resistance to trastuzumab include bypass mechanisms, mutations of the HER2 target, masking of HER2 proteins, inhibition of insulin-like growth factor, and phosphatase and tensin homologue (PTEN) deficiency. Many therapies are being developed to target these mechanisms in patients with HER2-positive, trastuzumab-resistant breast cancer. Additionally, treatment strategies other than trastuzumab with unique mechanisms of action are being assessed in this specific group of patients. In this review, we discuss the emerging data assessing therapeutic approaches in the management of trastuzumab-resistant HER2-positive disease.
引用
收藏
页码:1179 / 1187
页数:9
相关论文
共 76 条
[1]   Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab [J].
Adams, CW ;
Allison, DE ;
Flagella, K ;
Presta, L ;
Clarke, J ;
Dybdal, N ;
McKeever, K ;
Sliwkowski, MX .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) :717-727
[2]   Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].
Agus, DB ;
Akita, RW ;
Fox, WD ;
Lewis, GD ;
Higgins, B ;
Pisacane, PI ;
Lofgren, JA ;
Tindell, C ;
Evans, DP ;
Maiese, K ;
Scher, HI ;
Sliwkowski, MX .
CANCER CELL, 2002, 2 (02) :127-137
[3]  
ANDRE F, 2009, P AM SOC CLIN ONCO S, V26
[4]  
[Anonymous], BREAST CANC RES T S1
[5]  
[Anonymous], SAN ANT BREAST CANC
[6]  
BACHELOT T, 2008, 31 ANN SAN ANT BREAS
[7]   Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance [J].
Barok, Mark ;
Isola, Jorma ;
Palyi-Krekk, Zsuzsanna ;
Nagy, Peter ;
Juhasz, Istvan ;
Vereb, Gyorgy ;
Kauraniemi, Paivikki ;
Kapanen, Anita ;
Tanner, Minna ;
Vereb, Gyorgy ;
Szollosi, Janos .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (07) :2065-2072
[8]  
BASELGA J, 2007, P AM SOC CLIN ONCO S, V25
[9]   Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy [J].
Baxevanis, CN ;
Sotiropoulou, PA ;
Sotiriadou, NN ;
Papamichail, M .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (03) :166-175
[10]  
Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0